News List

PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials

Scientists from the University of Illinois at Urbana-Champaign and other institutes found that PAC-1

adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market

2022.12.12, the US FDA announced the approval of Mirati Therapeutics' oral KRAS G12C inhibitor a

New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

Abbvie announced that the European Commission has approved a new indication for Skyrizi, its novel a

HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!

AstraZeneca (AstraZeneca) recently reported positive, high-level results from its phase II trial of

Huatangning, the world's first new hypoglycemic drug was approved

Beijing, Oct. 9, 2022 -- Bayer announced that the global initiative for state and drug administratio

Haihe Pharmaceuticals' Paclitaxel Oral Solution China Marketing Authorization Application Officially Accepted

On September 13, 2022, Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. and South Ko

Using artificial intelligence to detect Parkinson's disease by reading people's breathing patterns

Parkinson's disease is notoriously difficult to diagnose because it relies primarily on the onse

Targeting specific DNA of Plasmodium may be effective in treating human malaria infection

Targeting a parasite's DNA could be a more effective way to combat malaria, new research from th

Vijoice is the first FDA-approved PRS treatment

2022.04.06, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelera

Systemic lupus erythematosus (SLE) oral new drug! BMS Novel Oral TYK2 Inhibitor deucravicitinib

Bristol-Myers Squibb (BMS) recently announced positive results from the Phase 2 PAISLEY study (NCT03